THERAVANCE BIOPHARMA INC (TBPH) Forecast, Price Target & Analyst Ratings

NASDAQ:TBPHKYG8807B1068

Current stock price

14.33 USD
+0.32 (+2.28%)
At close:
14.33 USD
0 (0%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for THERAVANCE BIOPHARMA INC (TBPH).

Forecast Snapshot

Consensus Price Target

Price Target
$27.25
+ 90.15% Upside

Next Earnings Forecast

Earnings Estimate
Release Date
May 6, 2026
Period
Q4 / 2025
EPS Estimate
$1.24
Revenue Estimate
59.673M

ChartMill Buy Consensus

Rating
81.54%
Weighted Analyst Rating Score

Price Target Details & History

Consensus Price Target and Range

Mean target
$27.25
Upside
+ 90.15%
From current price of $14.33 to mean target of $27.25, Based on 13 analyst forecasts
Low
$13.13
Median
$27.54
High
$44.10

Price Target Revisions

1 Month
0.00%
3 Months
0.00%

Price Target Summary

13 Wall Street analysts provided a forecast for the next 12 months for TBPH. The average price target is 27.25 USD. This implies a price increase of 90.15% is expected in the next year compared to the current price of 14.33.

Analyst Ratings & History

Current Analyst Ratings

TBPH Current Analyst RatingTBPH Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 1 2 3 4 5

Analyst Ratings History

TBPH Historical Analyst RatingsTBPH Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6 8 10

Analyst Ratings Consensus

ChartMill Buy Consensus
81.54%
TBPH was analyzed by 13 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about TBPH.
In the previous month the buy percentage consensus was at a similar level.
TBPH was analyzed by 13 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-03-20BTIGReiterate Buy -> Buy
2026-03-05OppenheimerDowngrade Outperform -> Perform
2026-03-04B. Riley SecuritiesDowngrade Buy -> Neutral
2026-03-04HC Wainwright & Co.Maintains Buy -> Buy
2026-03-03BTIGMaintains Buy -> Buy
2026-03-02HC Wainwright & Co.Maintains Buy -> Buy
2026-02-03BTIGReiterate Buy -> Buy
2025-12-03OppenheimerInitiate Outperform
2025-11-26BTIGMaintains Buy -> Buy
2025-11-11HC Wainwright & Co.Maintains Buy -> Buy
2025-09-12B. Riley SecuritiesInitiate Buy
2025-06-27BTIGMaintains Buy -> Buy
2025-06-17Jones TradingInitiate Buy
2025-02-27HC Wainwright & Co.Reiterate Buy -> Buy
2025-02-25HC Wainwright & Co.Reiterate Buy -> Buy
2024-09-16HC Wainwright & Co.Reiterate Buy -> Buy
2024-08-06Leerink PartnersDowngrade Outperform -> Market Perform
2024-08-06TD CowenMaintains Hold -> Hold
2024-08-06HC Wainwright & Co.Maintains Buy -> Buy
2024-05-29HC Wainwright & Co.Reiterate Buy -> Buy
2024-05-14HC Wainwright & Co.Reiterate Buy -> Buy
2024-04-12BTIGInitiate Buy
2023-08-08HC Wainwright & Co.Reiterate Buy -> Buy
2023-05-09HC Wainwright & Co.Maintains Buy
2023-02-28HC Wainwright & Co.Reiterate Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 6, 2026
Period
Q4 / 2025
EPS Estimate
$1.24
Revenue Estimate
59.673M
Revenue Q2Q
218.19%
EPS Q2Q
501.22%
Number of Analysts
9

Next Earnings Revisions

Revenue (1 Month)
15.03%
Revenue (3 Months)
15.18%
EPS (1 Month)
8.35%
EPS (3 Months)
8.53%

Next Earnings Summary

TBPH is expected to report earnings on 5/6/2026. The consensus EPS estimate for the next earnings is 1.24 USD and the consensus revenue estimate is 59.67M USD.
The next earnings revenue estimate has been revised upward by 15.18% in the past 3 months. Upward revisions are a positive sign and indicate that analysts are more optimistic about the next earnings compared to 3 months ago.

Full Analyst Estimates

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
TBPH revenue by date.TBPH revenue by date.
51.3M
-7.23%
57.424M
11.94%
64.381M
12.12%
113.6M
76.45%
117.68M
3.59%
90.368M
-23.21%
182.37M
101.81%
205.05M
12.44%
219.91M
7.25%
276.56M
25.76%
430.54M
55.68%
641.27M
48.95%
EBITDA
YoY % growth
TBPH ebitda by date.TBPH ebitda by date.
-75.38M
67.48%
-51.291M
31.96%
-40.726M
20.60%
N/AN/AN/AN/AN/AN/AN/AN/AN/A
EBIT
YoY % growth
TBPH ebit by date.TBPH ebit by date.
-79.1M
66.72%
-53.292M
32.63%
-42.436M
20.37%
-616.927K
98.55%
42.411M
6,974.56%
28.588M
-32.59%
33.866M
18.46%
13.872M
-59.04%
64.77M
366.91%
499.91M
671.82%
385.76M
-22.83%
421.06M
9.15%
Operating Margin
TBPH operating margin by date.TBPH operating margin by date.
-154.19%-92.80%-65.91%-0.54%36.04%31.64%18.57%6.77%29.45%180.76%89.60%65.66%
EPS
YoY % growth
TBPH eps by date.TBPH eps by date.
-0.67
77.29%
-0.97
-44.78%
-1.09
-12.37%
1.93
277.49%
0.96
-50.18%
-0.05
-105.50%
0.82
1,651.35%
0.48
-41.12%
0.68
40.00%
1.59
134.59%
1.69
6.41%
N/A

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q4 / 25 Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26
EPS
Q2Q % growth
1.24
501.22%
-0.06
77.71%
-0.13
75.30%
-0.09
-229.32%
1.47
18.46%
Revenue
Q2Q % growth
59.673M
218.19%
24.317M
58.03%
21.665M
-17.29%
25.296M
26.54%
48.511M
-18.71%
EBITDA
Q2Q % growth
N/AN/AN/AN/AN/A
EBIT
Q2Q % growth
32.28M
450.87%
-9.869M
31.63%
-8.185M
-200.39%
-7.14M
-10.61%
24.837M
-23.06%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

TBPH Yearly Revenue VS EstimatesTBPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M
TBPH Yearly EPS VS EstimatesTBPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
24.96%
EPS Next 5 Year
19.57%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
12.20%
Revenue Next 5 Year
26.23%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A

THERAVANCE BIOPHARMA INC / TBPH Forecast FAQ

Can you provide the average price target for THERAVANCE BIOPHARMA INC stock?

13 analysts have analysed TBPH and the average price target is 27.25 USD. This implies a price increase of 90.15% is expected in the next year compared to the current price of 14.33.

What is the next earnings date for TBPH stock?

THERAVANCE BIOPHARMA INC (TBPH) will report earnings on 2026-05-06.

What are the consensus estimates for THERAVANCE BIOPHARMA INC (TBPH) next earnings?

The consensus EPS estimate for the next earnings of THERAVANCE BIOPHARMA INC (TBPH) is 1.24 USD and the consensus revenue estimate is 59.67M USD.

What is the expected long term growth rate for TBPH stock?

The expected long term growth rate for THERAVANCE BIOPHARMA INC (TBPH) is 12.2%.